key: cord-0869259-o43e6aid
authors: Beeraka, Narasimha M.; Sukocheva, Olga A.; Lukina, Elena; Liu, Junqi; Fan, Ruitai
title: Development of antibody resistance in emerging mutant strains of SARS CoV‐2: Impediment for COVID‐19 vaccines
date: 2022-04-13
journal: Rev Med Virol
DOI: 10.1002/rmv.2346
sha: 96c513b26fe38943428e3484e429a67455ba86b3
doc_id: 869259
cord_uid: o43e6aid

Coronavirus disease 2019 (COVID‐19) is caused by severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2), a highly infectious agent associated with unprecedented morbidity and mortality. A failure to stop growth of COVID‐19‐linked morbidity rates is caused by SARS‐CoV‐2 mutations and the emergence of new highly virulent SARS‐CoV‐2 strains. Several acquired SARS‐CoV‐2 mutations reflect viral adaptations to host immune defence. Mutations in the virus Spike‐protein were associated with the lowered effectiveness of current preventive therapies, including vaccines. Recent in vitro studies detected diminished neutralisation capacity of vaccine‐induced antibodies, which are targeted to bind Spike receptor‐binding and N‐terminal domains in the emerging strains. Lower than expected inhibitory activity of antibodies was reported against viruses with E484K Spike mutation, including B.1.1.7 (UK), P.1 (Brazil), B.1.351 (South African), and new Omicron variant (B.1.1.529) with E484A mutation. The vaccine effectiveness is yet to be examined against new mutant strains of SARS‐CoV‐2 originating in Europe, Nigeria, Brazil, South Africa, and India. To prevent the loss of anti‐viral protection in vivo, often defined as antibody resistance, it is required to target highly conserved viral sequences (including Spike protein) and enhance the potency of antibody cocktails. In this review, we assess the reported mutation‐acquiring potential of coronaviruses and compare efficacies of current COVID‐19 vaccines against ‘parent’ and ‘mutant’ strains of SARS‐CoV‐2 (Kappa (B.1.617.1), Delta (B.1.617.2), and Omicron (B.1.1.529)).

Alpha-and beta-CoVs can infect bats, pigs, cats, mice, and humans, [3] [4] [5] [6] [7] [8] [9] whereas the gamma-and delta-CoVs were shown to infect birds and mammals [10] [11] [12] [13] (Table 1) .

Recently classified coronaviruses (the family Coronaviridae) are represented by 45species (the latest confirmed count, 4 August 2021 15 ) that are grouped in 25 subgenera and 4 genera. 16 The significant changes in CoV taxonomy happened during 2021 years and 39 species (27 subgenera and five genera) were reported in 2020. 15 The list of species is most likely will be extended and adjusted, considering that during 15-year period (2003-2018) 339 SARS-CoV genomes were identified, including 274 CoV genomes from humans. 1 The most recent addition is Omicron variant 17 which is required to be classified by International Committee on Taxonomy of Viruses.

For some CoVs discovered in metagenomics studies, host and virus pathogenicity remains unknown, 18 while the genome sequence is the only known characteristic. 15 Currently, 58 complete genome sequences have been reported for Orthocoronavirinae subfamily including 24 genomes for alpha-CoVs, 18 for beta-CoVs, 10 for delta-CoVs, 5 for gamma-CoVs, and yet-to-be-identified number of subfamilies for Omicron (Table 1) . [19] [20] [21] [22] Increasing population immunity, a product of natural infections and immunizations, is predicted to amplify the selection pressure on the mutating virus and increase the evolution of mutants towards emergence of antibody resistant strains.

Human coronavirus NL63 (HCoV-NL63) and 229E (HCoV-229E) were identified as alpha-CoVs. 23, 24 Human coronavirus HKU1 (HCoV-HKU1), OC43 (HCoV-OC43, SARS-CoV, MERS-CoV), and SARS-CoV-2 (the causative agent of coronavirus disease 2019 ) were grouped as beta-CoVs. [25] [26] [27] [28] [29] [30] [31] [32] The phylogenetic analysis of CoVs revealed that SARS-CoV-2 is more closely related to bat-SL-CoV ZXC21 and bat-SL-CoV ZC45, and more distantly related to SARS-CoV. 33 Beta-(HCoV-OC43 and HCoV-HKU1) and alpha-CoVs (HCoV-229E and HCoVNL63) were shown to infect the upper respiratory tract and cause mild respiratory diseases in humans and animals. 13, [15] [16] [17] [18] [19] [20] [21] [22] [23] Similar infection-related symptoms were recorded for the most recent variant (Omicron). 17 The lower respiratory tract infection with SARS-CoV, SARS-CoV-2, and MERS-CoV provoked various degrees of respiratory syndromes and extrarespiratory complications in humans. 21, 34 According to the World Health Organization (WHO) statistical report, 35 nearly 350 million COVID-19 infection cases have been reported on 24 January 2022. The number of SARS-CoV-2-infected patients and related death is constantly growing. 36 The pandemic resulted in nearly 6 million deaths worldwide. 35 COVID-19 infection rate increased globally due to the emergence of mutant SARS-CoV-2 strains and lack of efficient anti-viral agents. In this review, we discuss the integrated genome and emergence of mutant variants of SARS-CoV-2. The efficacy of existing SARS-CoV-2 vaccines is assessed to accentuate the urgent need for the vaccine amendment and design of complex approaches in vaccination schemes. The study also evaluates the progress of SARS-CoV-2 mutations towards development of antibody resistance in mutant strains of this virus. As predicted, emergence of variants of concern (VOCs), including highly infectious delta and omicron strains, indicates direction of viral mutations towards less severe, but more spreadable VOCs. Higher transmissibility was reported for the most recent VOC Omicron codes contain information about polyprotein 1a and 1b that can be consequently cleaved into 16 non-structural proteins (NSP) by specific proteases (chymotrypsin like protease (3CLpro), main protease, and papain like protease. 33, 52, 53 Genes coding for accessory proteins were also reported in 3 0 region. 33 HCoV-OC43 and HCoV-HKU1 were shown to encode haemagglutinin esterase (HE) gene. [54] [55] [56] CoVs from different viral groups express various numbers of accessory proteins that are not necessary for virus replication, but impact SARS pathogenicity. Notably, six additional ORFs (ORF3a, ORF6, ORF7a, ORF7b, ORF8, and ORF10) that are located between structural genes, may code more accessory proteins. 57 SARS-CoV genome contains codes for eight accessory proteins (3a, 3b, 6, 7a, 7b, 8a, 8b, and 9b). 58, 59 Genome of MERS-CoV(≈30 kb) encodes ORF1a (NSP1-11), ORF1b (NSP12-16), four structural proteins (S, E, M, and N), and five accessory proteins (3, 4a, 4b, 5 , and 8b). 60 The trimeric, cell-surface glycoprotein spike (S-protein) was identified as a potential SARS-CoV-2 therapeutic target responsible for the binding and penetration of the virus to the host cells. However, S-proteins are required to be primed (cleaved) by the host serine protease TMPRSS2. 64 The S-protein priming allows successful virus binding the angiotensin-converting enzyme 2 (ACE2), a receptor for the entry of both SARS-CoV and SARS-CoV-2 viruses. Cell entrance of MERS-CoV is mediated by a different receptor, dipeptidyl peptidase 4 (DPP4). 65 Variations (mutations) in the S-protein are associated with the host tissue tropism and severity response range to CoVs. 65 Genomic sequencing analysis of S-protein structure in SARS-CoV and SARS-CoV-2 delineated 76% sequence homology.

Both SARS-CoV and SARS-CoV-2 share eight conserved binding positions and six semi-conserved positions in S-protein domains. 66, 67 Aside from ACE2, SARS-CoV-2 S-protein was shown to interact with neuropilin 1 (NRP1) 68 and Basigin2/EMMPRIN/CD147 (CD147). 69 The involvement of CD147 in pathogenesis of other widely spread and highly harmful viruses was demonstrated. 70 

Several biological functions of SARS-CoV-2 accessory proteins have been described. For instance, 3a and 3b proteins were shown to activate apoptosis and stimulate release of proinflammatory cytokines. 71 Alternatively, protein 6 blocked pro-inflammatory interferon (INF) signalling, but stimulated DNA synthesis. Activation of nuclear factor kappa B (NF-κB)by ORF3a, M, ORF7a, and N proteins was reported. 72 Accordingly, ORF7a was indicated as a promising antiinflammatory therapeutic target in COVID-19 patients. 72 Previously, SARS-CoV protein 7a was also shown to trigger NF-κB and mitogen-activated protein kinase p38 (MAPK) signalling pathways. 73, 74 Alternatively, it was reported that SARS-CoV structural M protein can block NF-κB activity in cell models in vitro, 75 suggesting complex involvement of viral proteins in the regulation of proinflammatory pathways. The functional role of protein 7b remains unclear. ORF3b, ORF6, ORF7a and ORF8 may interfere with IFN type I pathway and damage host immunity. 76 Moreover, protein 8 (ORF8a and ORF8b) induces endoplasmic reticulum (ER) stress and triggers the activating transcription factor 6 (ATF6), responsible for the regulation of unfolded protein responses. 77 Interestingly, it seems that signalling roles of protein 8a and 8b are different. Protein 8a was detected to activate caspase-dependent apoptosis, whereas protein 8b may impact host DNA synthesis. Intracellular roles and structure of SARS-CoV-2 accessory proteins was recently reviewed. 76 

Since the beginning of COVID-19 outbreak in Wuhan (China), over 12,000 mutations have been observed in the reference SARS-CoV-2 sequence (hCoV-19/Wuhan/WIV04/2019). 78 every ≈11 days. 79 Consequently, over 1.4 million SARS-CoV-2 sequences, including 3913 major representative variants genomes, have been detected worldwide and stored in the global SARS-CoV-2 sequence database (Global Initiative on Sharing Avian Influenza Data (GISAID)). 80 Notably, functional changes in major SARS proteins associated with virus infectivity were preceded by limited numbers of genetic mutations that will be discussed in this review. genome, a key region for NSP mutations, have largely unclear consequences for human health 86 and require thorough investigation.

The main function of S-protein of SARS-CoV-2 is associated with the targeted binding to ACE2 receptors and receptor-facilitated intracellular transmission. 66 Gussow et al. , assessed the role of Sprotein and other components and characteristics of SARS-CoV-2, SARS-CoV, and MERS-CoV. 87 Enhanced virulence of SARS variants was linked to the mutations pertaining to S-protein mutations that allowed a better cell binding and promoted higher fatality rates. 88 Multiple SARS-CoV-2 mutant variants with high virulence were reported. 89 For instance, African and Asian countries were marked by the highest percentages of unique mutations in S-proteins. 90 European and North American S-protein variants were marked by a larger number of diverse haplotype blocks that contained nonsynonymous variants. 84, 88 Among all the variants, mutations in S-protein were associated with higher virulence and, therefore, S-protein is considered to be the most significant target for neutralising antibodies and vaccine development. 84, 88 However, recently reports delineated the emergence of more virulent double mutant strains of SARS-CoV-2 64 which suggests that several targets (including, but not limited to Sprotein) should be considered during the development of more effective vaccines.

Mutations in NSP1 of ORF1a/ORF1b were directly associated with abnormal levels of virulence and transmissibility. Accordingly, antibodies against NSP1 were shown to regulate and antagonise viral replication. 91, 92 Mutations in ORF allow the generation viral proteins which can induce MHC-I expression in the infected hosts and promote viral escape from immune surveillance. 93, 94 It has been shown that Alpha variant contains ORF with a premature stop codon at 27 th position. 95 Interestingly, partial deletions of NSP1 and ORF8 (Δ382 variant in Singapore) were observed in VOCs detected in Sichuan, China (NSP1: Δ500-532 variant). [92] [93] [94] A side from NSP1, non-RBD regions mutation D614G is one of the most widely occurring mutations reported in 99% of current variants. 96, 97 The mutation helps to enhance S-protein density, prevent S2 shedding, and facilitate a higher infection rate. 98, 99 Higher rate of deletions was also detected in antibodies-recognising domain (N-terminus region of S1 subunit. 100 For instance, Alpha and Beta variants were shown to contain numerous mutations in S1 subunit, including ΔRDR1 mutations were observed at a higher frequency (<50%) in Indian isolates. 102 Alternatively, G25563T (in ORF3a), C26735T (in NSP14), and C18877T (in M protein) mutations were observed less frequently (15%) in the Indian genome. 102 Further analysis demonstrated the presence of 4 silent mutations (in D294D/S, F106F/NSP3, S76S/NSP4 and Y789Y/S) without an apparent effect in the protein structure modulation. However, it was suggested that these mutations may influence the codon usage and modulate the translation process. 103 Mutation observed in the 5 0 -UTR region could impact protein folding and transcription of SARS-CoV-2 genome. 103 Specific mutations in S-protein (L54F, G339S) , and N-protein (S194L) coding genes were unique to Indian isolates. 27,28 L54F, K77M, and R88M mutations were identified in the N-terminal domain (NTD) domain of S1 subunit. NTD mutations were suggested to impact the virus binding ability in host cells. 105 Mutations of E583D and Q677H in the linker domain located in between S1 and S2 subunits could also influence the virus entry via modulating the serine proteases. 105 

K77M, R78M, D294D, E583D, Q677H), 103,104 NSP3 (G716I, T749I, A994D, D1121G, S1197R), RdRp/NSP12 (A97V, L329I, G571S, V880I), NSP2 (S301F,

Whole genome sequencing technique was used to analyse thousands of SARS-CoV-2 isolates around the world. SARS-CoV-2 genome sequences were organised into haplotype groups [111] [112] [113] that were later extended and adjusted using data from 56 countries/territories. The large collection of data is stored at the GISAID database and contains information about 66 common haplotypes. 114 Information about SARS-CoV-2 genome mutations (global data from 48 countries) was also collected and stored in the Children's Hos- Omicron and Delta contain two similar RBD mutations that lead to Sprotein modifications, increased ACE2 binding affinity, and ability to evade immune surveillance. 133, 134 Notably, S-protein is the target of T-cell neutralising antibodies during clearance of the viral infection.

Comparing the variant infection rate, it was found that omicron is four times more infectious than the wild type and twice more than the Delta variant. 36 However, it was recently demonstrated that additional (booster) mRNA vaccine doses may help to improve antiviral antibody responses against new SARS-CoV-2 variants. 135 It was also noted that Omicron is rapidly spreading, 133, 136 escaping from the convalescent sera. 131, 137, 138 Two-dose course with existing vaccine indicated escape of omicron from immune crossneutralisation. 37 The adjusted OR among Delta cases versus unvaccinated was 0.065 (95% CI, 0.059-0.071), indicating a better protection against Delta. 138 The data may be called preliminary as the study included only 244 Omicron and 679 Delta cases injected with third dose of vaccine. 138 Notably, extended intervals (>42 days) between second and 3 rd vaccine doses provided better immunogenicity. 38, 39, 139 A significant gain in the neutralisation activity against Omicron has been observed in the individuals who received vaccination of third dose (booster) of mRNA vaccine (6 months after second dose). [140] [141] [142] BNT162b2 third dose was also more effective against Beta and Delta variants. 143, 144 Future studies should evaluate Omicron variant resistance to the other vaccine-generated responses.

Despite mutations across the S-protein's RBD region could support a strain resistance against host immunity, 74-76 NTD-located mutations may provide an additional pathway for the viral escape from antibody-based neutralisation. [145] [146] [147] Antibody-linked sensitivity and infection spread were recently associated with the natural mutations in NTD. 148 Polyclonal antibodies generated by the human immune system were shown to bind to the several RBD sites that are undergoing intense evolutionary changes. 149 Therefore, current RBD-targeting antibodies alone may not provide an efficient protection from the virus. 150 It was suggested to search for the non-RBD-targeting antibodies and design antibody cocktails. This suggestion requires experimental confirmation. (Figure 2 ). Asp-480 and Gly-480 can also confer viral adaptation in order to bind A to CE2. 155 Another mutation L472F can reinforce RBD/hACE2 interactions. However, L472P can weaken the interactions of RBD with ACE2 due to steric clash of Phe-472 with Thr-82 in chimeric ACE2. 155 Exact molecular and structural mechanisms underlying the mutant-host interactions are not completely clarified and require further investigation. It is also necessary to elucidate the mechanism of natural selection of RBD-located mutation.

Similarly, the enhancement in virulence was observed in the mutated strains of MERS-CoV. Unique amino acid substitutions of eight MERS-CoV isolates were observed in ORF1ab (41 mutations), N-protein (10 mutations), S-protein (9 mutations), and ORF4b (5 mutations). 156, 157 Distinct to SARS, a low mutation rate was observed in MERS-CoV strains isolated from the humans. It was attributed to the decline in immunological pressure against MERS-CoV strains in humans. 158 Furthermore, random mutations were BEERAKA ET AL. also observed in nsp1-nsp3, nsp12, nsp13, and nsp16 (ORF1ab replicase) (Figure 2 ). 156 S1 and S2 subunits of S-protein in MERS-CoV were shown to gain substitutions (such as T424I, S459T, W553R) in RBD. 159 The S2 subunit-located substitutions S950T, Q1009L, and C1313S were also observed in the fusion peptide, heptad repeat region-1, and transmembrane region, respectively. 156 In addition, MERS-CoV key-components for regulation of viral genomic RNA were also shown to contain substitutions, including V178A (in NTD), A300 (in C-terminal domain (CTD)) G198S, D242E, S11F, P7L, and G28V (in N-arm). 83 Several substitutions (L293F, V263A, R292P, and W293C) were detected at the MERS-CoV CTD region. 156 Similar to other Beta-coronaviruses, the MERS-CoV encodes 5 accessory proteins (ORF3, ORF4a/4b, ORF5, and ORF8b). 159 

The adapted phylogenetic strategies including WGS, analysis of mutational variations in nucleotide sequences, and microsatellite analysis were used to understand, compare, and predict evolutionary development of coronaviruses. 160 

During the development of COVID-19 vaccines, the key-role of Sprotein in the interaction of the virus with human ACE2 receptors was considered as the leading factor for the onset of infection. Therefore, current vaccines and available antibodies were designed to target the S-protein of the virus. The S-protein RBD and NTD are the current targets of most vaccine-generated neutralising antibodies. Notably, anti-RBD antibodies are 10-to 100-fold more powerful than anti-NTD antibodies. 161 Anti-RBD antibody pool in convalescent patients represents 90% of the serum-circulating neutralising activity, 162 thus confirming the importance of this region.

Variations in RBD mutations are limited as virus has to maintain its ACE2-binding capacity. Alternatively, NTD encoding sequence is more open for mutational variability. 163 However, the receptor binding motif of S-protein has operational plasticity and excessive mutations in RBD, which may abrogate the antibody efficacy after vaccination. 164 The currently available anti-COVID-19 vaccines and their targets are discussed below.

It is mRNA-based vaccine with a high level of safety 165 and act against the full-length Spike gene. Vaccination with this agent resulted in the formation of persistent germinal centres and B cellbased responses associated with the generation of strong humoral immunity. 166 As a promising sign of long lasting immunity, the presence of plasmablast responses was also reported. 167 It has been previously shown that antigen-specific germinal B cells may remain functional for a year. 168, 169 However, the vaccine induced production of fewer antibodies targeting NTD of the S-protein, 166 Both BNT162b2 and mRNA-1273 vaccines were shown to generate IgM/IgG responses and provide good humoral anti-viral immunity. 171, [173] [174] [175] [176] [177] However, these vaccines were only partially protective against VOCs with RBD mutations. 171, 173, 174, 177 Vaccineinduced neutralisation efficacy of 14 out of 17 detected antibody types declined against variants with K417N, or E484K, or N501Y mutations. [178] [179] [180] [181] [182] VOCs with E484K and Q493R mutations exhibited resistance to class 2 antibodies; whereas variants with R346S, N439K, and N440K mutations resisted class 3 antibodies. [178] [179] [180] [181] [182] EpiVacCorona (developed by the Vektor State Research Centre of Virology and Biotechnology in Russia) has just been approved in 3 countries. It is a multi-epitope vaccine which targets several regions, including the RBD region in the S2 protein, M, and N proteins. 174, 183 Sputnik V (also known as Gam-Covid-Vac) vaccine is an adenovirus humoral and cellular immune responses. 190, 191 NVX-CoV2373 (Novavax) , recombinant S-protein/nanoparticle (Matrix-M) adjuvant vaccine, was found highly immunogenic. 192, 193 The efficacy of this vaccine against new variants was not reported.

Biotechin (Table 2 ).

The Epidemiological reports indicated that SARS variants with the emerging D614G amino acid (AC) mutation in S-protein RBD demonstrated a higher virulence and more severely affected the exposed population, compared to the reference strain. 202 The presence of G614 form was also associated with the substantial rise in viral load and infectivity as the conformation delivers a greater capability for binding to the human ACE2 receptor. 202 The G614

variant exhibited a greater replication rate than the ancestral D614 strain in both cell lines and primary airway human epithelial cells.

G614 variants were more resistant to the vaccine administration. 202, 203 Majority of vaccines have been designed to target S-protein to block its binding to ACE2 receptors. However, the vaccine-induced antibodies may not effectively recognise mutant variants of SARS-CoV-2 for neutralisation. 204 

Emergence of SARS-CoV-2 mutants indicates that COVID-19

pandemic is transforming into an ongoing wave-like SARS epidemic.

Various SARS strains are detected nearly every day all over the world. It is predictable that new highly virulent strains will appear in the near future in different parts of the world. 20, 51 Unfortunately, there is currently no guarantee that existing vaccines can provide required protection against the emerging strains. 209 However, vaccines that target S-protein domains demonstrated encouraging data and lead to the generation of broadly neutralising antibodies.

Promising results were also demonstrated after introduction of mRNA vaccine boosts that lead to 1000-fold increase in neutralising titres. [234] [235] [236] The data indicated that first-generation vaccines can prime the immune system and, after introduction of a booster, it is possible to provide protection against emerging strains. Another possibility is to use antibody cocktails and generate immunity to a large set of SARS variants. Application of antibody-based therapy should be used cautiously, aiming to avoid the emergence of antibody-resistance mutations. 209 

The manuscript preparation was financially supported by National Natural Science Foundation of China (No. 81700729).

Authors declare no conflicts of interest.

Not applicable.

All authors were involved in the design, conceptualisation, and 

Not applicable.

Not applicable.

https://orcid.org/0000-0003-3401-4315

Molecular epidemiology, evolution and phylogeny of SARS coronavirus

Changes to taxonomy and the international code of virus classification and nomenclature ratified by the International Committee on Taxonomy of Viruses

Isolation and serial propagation of porcine epidemic diarrhea virus in cell cultures and partial characterization of the isolate

Bats are natural reservoirs of SARS-like coronaviruses

Identification of a novel coronavirus in bats

Ecology, evolution and classification of bat coronaviruses in the aftermath of SARS

An update on feline infectious peritonitis: virology and immunopathogenesis

Detection of murine herpesvirus 68 (MHV-68) in dermacentor reticulatus ticks

Origin and evolution of pathogenic coronaviruses

Comparative analysis of complete genome sequences of three avian coronaviruses reveals a novel group 3c coronavirus

Discovery of seven novel Mammalian and avian coronaviruses in the genus deltacoronavirus supports bat coronaviruses as the gene source of alphacoronavirus and betacoronavirus and avian coronaviruses as the gene source of BEERAKA ET AL

Discovery of a novel bottlenose dolphin coronavirus reveals a distinct species of marine mammal coronavirus in gammacoronavirus

Origin, evolution, and virulence of porcine deltacoronaviruses in the United States

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) sequences in NCBI cirus

The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2

Additional changes to taxonomy ratified in a special vote by the international committee on taxonomy of viruses

Omicron variant of SARS-CoV-2: genomics, transmissibility, and responses to current COVID-19 vaccines

Expanding the RNA virosphere by unbiased metagenomics

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) sequences in NCBI virus

The current status and challenges in the development of vaccines and drugs against Severe Acute Respiratory Syndrome-Corona Virus-2 (SARS-CoV-2)

The beneficial effects of QIAPI 1® against pentavalent arsenic-induced lung toxicity a hypothetical model for SARS CoV2-induced lung toxicity

Strategies for targeting SARS CoV-2: small molecule inhibitors-the current status

A new virus isolated from the human respiratory tract

Human coronavirus NL63 infection and other coronavirus infections in children hospitalized with acute respiratory disease in Hong Kong, China

Identification of a novel coronavirus in patients with severe acute respiratory syndrome

A novel coronavirus associated with severe acute respiratory syndrome

An outbreak of coronavirus OC43 respiratory infection in Normandy, France

Characterization and complete genome sequence of a novel coronavirus, coronavirus HKU1, from patients with pneumonia

Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia

Vaccines for the prevention against the threat of MERS-CoV

Recent advances in the detection of respiratory virus infection in humans

A novel coronavirus from patients with pneumonia in China

Emerging coronaviruses: genome structure, replication, and pathogenesis

Features, evaluation and treatment coronavirus (COVID-19)

WHO Coronavirus (COVID-19) Dashboard

COVID-19 Effects on Geriatric Population and Failures of Aminoquinoline Therapy: Compilation of Studies from EU, USA, and China; Safety and Efficacy of Vaccines in the Prevention & Treatment of COVID-19

SARS-CoV-2 Omicron strain exhibits potent capabilities for immune evasion and viral entrance. Signal transduction and targeted therapy

Characterization of the novel SARS-CoV-2 omicron (B. 1.1. 529) variant of concern and its global perspective

Effectiveness of BNT162b2 vaccine against omicron variant in South Africa

Origin and evolution of pathogenic coronaviruses

Emerging coronaviruses: genome structure, replication, and pathogenesis

MERS: recent insights into emerging coronaviruses

The molecular biology of coronaviruses

Evidence for ACE2-utilizing coronaviruses (CoVs) related to severe acute respiratory syndrome CoV in bats

A structural analysis of M protein in coronavirus assembly and morphology

A severe acute respiratory syndrome coronavirus that lacks the E gene is attenuated in vitro and in vivo

Coronaviruses: an overview of their replication and pathogenesis

The nucleocapsid protein of coronaviruses acts as a viral suppressor of RNA silencing in mammalian cells

Genomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans

Evaluation of modified vaccinia virus Ankara based recombinant SARS vaccine in ferrets

A review on SARS-CoV-2-induced neuroinflammation, neurodevelopmental complications, and recent updates on the vaccine development

The molecular biology of coronaviruses

Virus-encoded proteinases and proteolytic processing in the Nidovirales

Coronaviridae. Virus Taxonomy: Ninth Report of the International Committee on Taxonomy of Viruses

The acetyl-esterase activity of the hemagglutinin-esterase protein of human coronavirus OC43 strongly enhances the production of infectious virus

Human coronavirus HKU1 spike protein uses O-acetylated sialic acid as an attachment receptor determinant and employs hemagglutinin-esterase protein as a receptor-destroying enzyme

Genomic characterization of a novel SARS-CoV-2

The genome sequence of the SARS-associated coronavirus

Unique and conserved features of genome and proteome of SARS-coronavirus, an early split-off from the coronavirus group 2 lineage

Genomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans

The human coronavirus disease COVID-19: its origin, characteristics, and insights into potential drugs and its mechanisms

A SARS-CoV-2 protein interaction map reveals targets for drug repurposing

The architecture of SARS-CoV-2 transcriptome

SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor

SARS-CoV-2 entry: at the crossroads of CD147 and ACE2

Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein

disease and diplomacy: GISAID's innovative contribution to global health

Neuropilin-1 is a host factor for SARS-CoV-2 infection

CD147-spike protein is a novel route for SARS-CoV-2 infection to host cells

The biological function and clinical utilization of CD147 in human diseases: a review of the current scientific literature

Accessory proteins of SARS-CoV and other coronaviruses

Activation of NF-κB and induction of proinflammatory cytokine expressions mediated by ORF7a protein of SARS-CoV-2

Augmentation of chemokine production by severe acute respiratory syndrome coronavirus 3a/X1 and 7a/X4 proteins through NF-κB activation

7a protein of severe acute respiratory syndrome coronavirus inhibits cellular protein synthesis and activates p38 mitogen-activated protein kinase

The membrane protein of SARS-CoV suppresses NF-κB activation

SARS-CoV-2 accessory proteins in viral pathogenesis: knowns and unknowns. Front Immunol

The ORF8 protein of SARS-CoV-2 induced endoplasmic reticulum stress and mediated immune evasion by antagonizing production of interferon beta

Antibody evasion by the P. 1 strain of SARS-CoV-2

Evolving biothreat of variant SARS-CoV-2-molecular properties, virulence and epidemiology

Global initiative on sharing avian influenza data (GISAID)

Characterizing genomic variants and mutations in SARS-CoV-2 proteins from Indian isolates

The current status and challenges in the development of vaccines and drugs against severe acute respiratory syndrome-corona virus-2 (SARS-CoV-2)

COVID-2019: the role of the nsp2 and nsp3 in its pathogenesis

The coronavirus is mutating -does it matter?

Effect of covid-19 vaccination on transmission of alpha and delta variants

Emerging SARS-CoV-2 variants of concern and potential intervention approaches

Genomic determinants of pathogenicity in SARS-CoV-2 and other human coronaviruses

Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 virus

Variant analysis of SARS-CoV-2 genomes

Global geographic and temporal analysis of SARS-CoV-2 haplotypes normalized by COVID-19 cases during the pandemic. Front Microbiol

Evasion of type I interferon by SARS-CoV-2

Genomic monitoring of SARS-CoV-2 uncovers an Nsp1 deletion variant that modulates type I interferon response

Structure of SARS-CoV-2 ORF8, a rapidly evolving immune evasion protein

Effects of a major deletion in the SARS-CoV-2 genome on the severity of infection and the BEERAKA ET AL

inflammatory response: an observational cohort study

Replicative fitness of a SARS-CoV-2 20I/501Y. V1 variant from lineage B. 1.1. 7 in human reconstituted bronchial epithelium. mBio

Deep mutational scanning of SARS-CoV-2 receptor binding domain reveals constraints on folding and ACE2 binding

Spike mutation D614G alters SARS-CoV-2 fitness

SARS-CoV-2 spike-protein D614G mutation increases virion spike density and infectivity

SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivo

Recurrent deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape

SARS-CoV-2 501Y. V2 variants lack higher infectivity but do have immune escape

Analysis of genomic distributions of SARS-CoV-2 reveals a dominant strain type with strong allelic associations

Geographic and genomic distribution of SARS-CoV-2 mutations

A genetic barcode of SARS-CoV-2 for monitoring global distribution of different clades during the COVID-19 pandemic

Structural and functional basis of SARS-CoV-2 entry by using human ACE2

Structure of the SARS-CoV nsp12 polymerase bound to nsp7 and nsp8 co-factors

Crystal structure of the severe acute respiratory syndrome (SARS) coronavirus nucleocapsid protein dimerization domain reveals evolutionary linkage between corona-and arteriviridae

Immune responses against SARScoronavirus nucleocapsid protein induced by DNA vaccine

Comprehensive analysis of genomic diversity of SARS-CoV-2 in different geographic regions of India: an endeavour to classify Indian SARS-CoV-2 strains on the basis of co-existing mutations

Pan-India novel coronavirus SARS-CoV-2 genomics and global diversity analysis in spike protein

Phylogenetic network analysis of SARS-CoV-2 genomes

Emerging SARS-CoV-2 mutation hot spots include a novel RNA-dependent-RNA polymerase variant

On the origin and continuing evolution of SARS-CoV-2

Distinct viral clades of SARS-CoV-2: implications for modeling of viral spread

Genetic spectrum and distinct evolution patterns of SARS-CoV-2

Characterizations of SARS-CoV-2 mutational profile, spike protein stability and viral transmission

A comprehensive review of viral characteristics, transmission, pathophysiology, immune response, and management of SARS-CoV-2 and COVID-19 as a basis for controlling the pandemic

Covid-19: new coronavirus variant is identified in UK

Evolution of the immune system in humans from infancy to old age

Structure of SARS coronavirus spike receptor-binding domain complexed with receptor

Structural basis for accommodation of emerging B. 1.351 and B. 1.1. 7 variants by two potent SARS-CoV-2 neutralizing antibodies

The emergence of new strains of SARS-CoV-2. What does it mean for COVID-19 vaccines?

Review of COVID-19 variants and COVID-19 vaccine efficacy: what the clinician should know?

SARS-CoV-2 spike L452R variant evades cellular immunity and increases infectivity

WHO. Tracking SARS-CoV-2 variants. 2021. 127. (GISAID)

Introduction of SARS-COV-2 C. 37 (WHO VOI lambda) from Peru to Italy

Association between interferon-lambda-3 rs12979860, TLL1 rs17047200 and DDR1 rs4618569 variant polymorphisms with the course and outcome of SARS-CoV-2 patients

A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2. Science

The omicron variant is highly resistant against antibody-mediated neutralizationimplications for control of the COVID-19 pandemic

Omicron and delta variant of SARS-CoV-2: a comparative computational study of spike protein

Omicron variant genome evolution and phylogenetics

Sequence analysis of the emerging sars-CoV-2 variant omicron in South Africa

Roles of the polybasic furin cleavage site of spike protein in SARS-CoV-2 replication, pathogenesis, and host immune responses and vaccination

SARS-CoV-2 omicron variant: characteristics and prevention

Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine-elicited human sera

Association between 3 doses of mRNA COVID-19 vaccine and symptomatic 18 of 21

infection caused by the SARS-CoV-2 omicron and delta variants

Immunogenicity of extended mRNA SARS-CoV-2 vaccine dosing intervals

Evolution of antibody immunity to SARS-CoV-2

Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection

Plasma neutralization of the SARS-CoV-2 omicron variant

Third BNT162b2 vaccination neutralization of SARS-CoV-2 Omicron infection

SARS-CoV-2 neutralization with BNT162b2 vaccine dose 3

N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2

In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies

An infectivity-enhancing site on the SARS-CoV-2 spike protein targeted by antibodies

Evolutionary dynamics of SARS-CoV-2 nucleocapsid protein and its consequences

Mapping mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies

Structural definition of a neutralization epitope on the N-terminal domain of MERS-CoV spike glycoprotein

Surveillance of SARS-CoV-2 in Frankfurt am main from October to december 2020 reveals high viral diversity including spike mutation N501Y in B. 1.1. 70 and B. 1.1. 7. Microorganisms

Receptor and viral determinants of SARS-coronavirus adaptation to human ACE2

Identification of two critical amino acid residues of the severe acute respiratory syndrome coronavirus spike protein for its variation in zoonotic tropism transition via a double substitution strategy

Structural analysis of major species barriers between humans and palm civets for severe acute respiratory syndrome coronavirus infections

Mechanisms of host receptor adaptation by severe acute respiratory syndrome coronavirus

Evolving sequence mutations in the Middle East respiratory syndrome coronavirus (MERS-CoV)

Comparative analysis of the genome structure and organization of the Middle East respiratory syndrome coronavirus (MERS-CoV) 2012 to 2019 revealing evidence for virus strain barcoding, zoonotic transmission, and selection pressure

Comparative genomic analysis MERS CoV isolated from humans and camels with special reference to virus encoded helicase

The role of severe acute respiratory syndrome (SARS)-coronavirus accessory proteins in virus pathogenesis

Comprehensive omparative genomic and microsatellite analysis of SARS, MERS, BAT-SARS, and COVID-19 coronaviruses

Extremely potent human monoclonal antibodies from COVID-19 convalescent patients

SARS-CoV-2 escaped natural immunity, raising questions about vaccines and therapies

Sensitivity of infectious SARS-CoV-2 B. 1.1. 7 and B. 1.351 variants to neutralizing antibodies

Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies

Impaired humoral and cellular immunity after SARS-CoV2 BNT162b2 (Tozinameran) prime-boost vaccination in kidney transplant recipients

SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses

A temporal switch in the germinal center determines differential output of memory B and plasma cells

Multiple layers of B cell memory with different effector functions

Different B cell populations mediate early and late memory during an endogenous immune response

Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data

Efectividad y seguridad de las vacunas para el SARS-CoV-2 actualmente disponibles. FMC-Formación Médica Continuada en Atención Primaria

Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants

Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine

An mRNA vaccine against SARS-CoV-2-preliminary report

Different dose regimens of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373) in younger and older adults: a phase 2 randomized placebocontrolled trial

Fab and Fc contribute to maximal protection against SARS-CoV-2 following NVX-CoV2373 subunit vaccine with Matrix-M vaccination

BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans

Evaluation of the mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates

Convergent antibody responses to SARS-CoV-2 in convalescent individuals

Fuggite da anticorpi neutralizanti da varianti di proteine spike SARS-CoV-2

SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies

Prospective mapping of viral mutations that escape antibodies used to treat COVID-19

Recombinant protein vaccines, a proven approach against coronavirus pandemics. Adv Drug Deliv Rev

Safety and efficacy of an rAd26 and rAd5 vector-based heterologous primeboost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia

Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial

Benefits and risks associated with different uses of the COVID-19 vaccine Vaxzevria: a modelling study

Thrombocytopenia and intracranial venous sinus thrombosis after "COVID-19 vaccine AstraZeneca" exposure

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a primeboost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial

Safety and efficacy of single-dose Ad26. COV2. S vaccine against Covid-19

Interim results of a phase 1-2a trial of Ad26. COV2. S covid-19 vaccine

Efficacy of NVX-CoV2373 covid-19 vaccine against the B. 1.351 variant

Safety and efficacy of NVX-CoV2373 Covid-19 vaccine

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial

Effectiveness of CoronaVac among healthcare workers in the setting of high SARS-CoV-2 Gamma variant transmission in Manaus, Brazil: a testnegative case-control study. Lancet Reg Health Am

COVID-19 Vaccine: a comprehensive status report

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebocontrolled, phase 1/2 clinical trial

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial

The enzymatic activity of the nsp14 exoribonuclease is critical for replication of MERS-CoV and SARS-CoV-2

Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccineelicited sera

A comprehensive review of viral characteristics, transmission, pathophysiology, immune response, and management of SARS-CoV-2 and COVID-19 as a basis for controlling the pandemic

Tracking changes in SARS-CoV-2 Spike: evidence that D614G increases infectivity of the COVID-19 virus

Emergence of a highly fit SARS-CoV-2 variant

SARS-CoV-2: vaccines in the pandemic era

SARS-CoV-2 501Y. V2 escapes neutralization by South African COVID-19 donor plasma

mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants

Sensitivity of SARS-CoV-2 B. 1.1.7 to mRNA vaccine-elicited antibodies

Antibody resistance of SARS-CoV-2 variants B. 1.351 and B. 1.1. 7

Evidence of escape of SARS-CoV-2 variant B. 1.351 from natural and vaccine-induced sera

New SARS-CoV-2 variantsclinical, public health, and vaccine implications

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B. 1.1. 7): an exploratory analysis of a randomised controlled trial

Neutralizing activity of BNT162b2-elicited serum

Neutralization of SARS-CoV-2 variants B. 1.429 and B. 1.351

SARS-CoV-2 variants B. 1.351 and P. 1 escape from neutralizing antibodies

Model-based estimation of transmissibility and reinfection of SARS-CoV-2 P. 1 variant

Genomics and epidemiology of the P. 1 SARS-CoV-2 lineage in Manaus

Neutralization of variant under investigation B. 1.617. 1 with sera of BBV152 vaccinees

Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-2 variant

California coronavirus strain may be more infectiousand lethal

South Africa suspends use of AstraZeneca's COVID-19 vaccine after it fails to clearly stop virus variant

Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity

Analysis of SARS-CoV-2 variant mutations reveals neutralization escape mechanisms and the ability to use ACE2 receptors from additional species

COVID-19 one year into the pandemic: from genetics and genomics to therapy, vaccination, and policy

Riding the waves of COVID-19 pandemics-a call for a multiobjective compromise

High genetic barrier to SARS-CoV-2 polyclonal neutralizing antibody escape

Efficacy of the ChAdOx1 nCoV-19 Covid-19 vaccine against the B. 1.351 variant

Efficacy of NVX-CoV2373 covid-19 vaccine against the B. 1.351 variant

Thrombotic thrombocytopenia after Ad26. COV2. S vaccination-response from the manufacturer

Efficacy of the ChAdOx1 nCoV-19 Covid-19 vaccine against the B. 1.351 variant

SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates. npj Vaccines

Antibody responses in seropositive persons after a single dose of SARS-CoV-2 mRNA vaccine

Evolutionary divergence and convergence in proteins In Evolving Genes and Proteins

Development of antibody resistance in emerging mutant strains of SARS CoV-2: impediment for COVID-19 vaccines